Erratum: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines (Journal of Hematology and Oncology (2013) 6 (92) DOI: 10.1186/1756-8722-6-92);Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Phillip, Cornel Joseph ^a,b   Zaman, Shadia ^a   Shentu, Shujun ^a   Balakrishnan, Kumudha ^a,b   Zhang, Jiexin ^a   Baladandayuthapani, Veera ^a,b   Taverna, Pietro ^c   Redkar, Sanjeev ^c   Wang, Michael ^a   Stellrecht, Christine Marie ^a,b   Gandhi, Varsha ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

amuvatinib; HGF; MET; MP470; Multiple myeloma

Indexed keywords

AMUVATINIB; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3; LENALIDOMIDE; MESSENGER RNA; PROTEIN TYROSINE KINASE; SYNDECAN 1;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CLINICAL ARTICLE; DISEASE COURSE; DNA SYNTHESIS; DRUG CYTOTOXICITY; FEMALE; GROWTH; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; MALE; MYELOMA; MYELOMA CELL; PLASMA CELL; PROTEIN PHOSPHORYLATION;

AGED; APOPTOSIS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84889860433     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0335-5     Document Type: Erratum

References (66)

1. Multiple myeloma: increasing evidence for a multistep transformation process. Hallek M, Bergsagel PL, Anderson KC, Blood 1998 91 3 21 9414264 (Pubitemid 28018724)
2. Towards a new age in the treatment of multiple myeloma. Piazza FA, Gurrieri C, Trentin L, Semenzato G, Ann Hematol 2007 86 159 172 10.1007/s00277-006-0239-5 17205287 (Pubitemid 46195988)
3. Latest advances and current challenges in the treatment of multiple myeloma. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K, Nat Rev Clin Oncol 2012 9 135 143 10.1038/nrclinonc.2012.15 22349016
4. Multiple myeloma. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC, Lancet 2009 374 324 339 10.1016/S0140-6736(09)60221-X 19541364
5. Targeting the bone microenvironment in multiple myeloma. Roodman GD, J Bone Miner Metab 2010 28 244 250 10.1007/s00774-009-0154-7 20127498
6. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Podar K, Anderson KC, Blood 2005 105 1383 1395 10.1182/blood-2004-07-2909 15471951 (Pubitemid 40223651)
7. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Derksen PW, De Gorter DJ, Meijer HP, Bende RJ, Van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST, Leukemia 2003 17 764 774 10.1038/sj.leu.2402875 12682635 (Pubitemid 36519374)
8. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Yasui H, Hideshima T, Richardson PG, Anderson KC, Br J Haematol 2006 132 385 397 16412014 (Pubitemid 43381614)
9. Cytokines and signal transduction. Hideshima T, Podar K, Chauhan D, Anderson KC, Best Pract Res Clin Haematol 2005 18 509 524 10.1016/j.beha.2005. 01.003 16026734 (Pubitemid 40984111)
10. IL-6 inhibits apoptosis of human myeloma cell line XG-7 through activation of JAK/STAT pathway and up-regulation of Mcl-1. Song L, Li Y, Sun YX, Yu M, Shen BF, Ai Zheng 2002 21 113 116 12479056
11. MET receptor tyrosine kinase as a therapeutic anticancer target. Stellrecht CM, Gandhi V, Cancer Lett 2009 280 1 14 10.1016/j.canlet.2008.10.045 19100682
12. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Naldini L, Vigna E, Ferracini R, Longati P, Gandino L, Prat M, Comoglio PM, Mol Cell Biol 1991 11 1793 1803 2005882 (Pubitemid 21895545)
13. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, Comoglio PM, Oncogene 1991 6 501 504 1827664 (Pubitemid 21924112)
14. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Rodrigues GA, Park M, Oncogene 1994 9 2019 2027 8208547 (Pubitemid 24194169)
15. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST, Blood 2002 99 1405 1410 10.1182/blood.V99.4.1405 11830493 (Pubitemid 34547098)
16. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Tjin EPM, Groen RWJ, Vogelzang I, Derksen PWB, Klok MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M, Blood 2006 107 760 768 10.1182/blood-2005-05-1929 16189274 (Pubitemid 43076403)
17. Exploiting the PI3K/AKT pathway for cancer drug discovery. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB, Nat Rev Drug Discov 2005 4 988 1004 10.1038/nrd1902 16341064
18. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A, Blood 1996 88 3998 4004 8916966 (Pubitemid 26383124)
19. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A, J Biol Chem 1996 271 24655 24661 10.1074/jbc.271.40.24655 8798732 (Pubitemid 26333208)
20. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The nordic myeloma study group. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A, Blood 1998 91 806 812 9446640 (Pubitemid 28078282)
21. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, Sundan A, Blood 2000 96 3139 3146 11049995
22. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E, Br J Haematol 2002 116 796 802 10.1046/j.0007-1048.2002.03364.x 11886383 (Pubitemid 34226998)
23. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Borset M, Waage A, Br J Haematol 2002 119 672 676 10.1046/j.1365-2141.2002.03898.x 12437643 (Pubitemid 35366207)
24. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS, Am J Hematol 2003 72 229 233 10.1002/ajh.10304 12666132 (Pubitemid 36383972)
25. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma. Kara IO, Sahin B, Gunesacar R, Unsal C, Adv Ther 2006 23 635 645 10.1007/BF02850052 17050506 (Pubitemid 44747444)
26. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Sezer O, Jakob C, Eucker J, Niemoller K, Gatz F, Wernecke K, Possinger K, Eur J Haematol 2001 66 83 88 10.1034/j.1600-0609.2001. 00348.x 11168514 (Pubitemid 32154100)
27. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, Buchler T, Penka M, Vorlicek J, Hajek R, Neoplasma 2010 57 29 34 10.4149/neo-2010-01-029 19895169
28. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Ludek P, Hana S, Zdenek A, Martina A, Dana K, Tomas B, Lucie K, Marta K, Jaroslav M, Miroslav P, et al. Eur J Haematol 2010 84 332 336 10.1111/j.1600-0609.2009.01396.x 20015241
29. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Pour L, Svachova H, Adam Z, Almasi M, Buresova L, Buchler T, Kovarova L, Nemec P, Penka M, Vorlicek J, Hajek R, Ann Hematol 2010 89 385 389 10.1007/s00277-009-0834-3 19784651
30. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Hjertner O, Torgersen ML, Seidel C, Hjorth-Hansen H, Waage A, Borset M, Sundan A, Blood 1999 94 3883 3888 10572104
31. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A, Blood 2007 109 3024 3030 17138824 (Pubitemid 46482103)
32. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V, Cancer Res 2007 67 9913 9920 10.1158/0008-5472.CAN-07-0770 17942923 (Pubitemid 47621240)
33. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V, Cancer Chemother Pharmacol 2009 63 587 597 10.1007/s00280-008-0770-2 18509644
34. RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Chen LS, Stellrecht CM, Gandhi V, Br J Haematol 2008 140 682 691 10.1111/j.1365-2141.2007.06955.x 18205859 (Pubitemid 351300913)
35. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Mahtouk K, Tjin EP, Spaargaren M, Pals ST, Biochim Biophys Acta 1806 2010 208 219
36. Dual inhibition of receptor tyrosine kinases of PDGFR and EGFR abolishes prostate cancer cell growth in a mouse xenograft model by complete dephosphorylation of PKB/Akt. Qi W, Cooke L, Calaluce R, Bearss D, Mahadevan D, Proc Am Assoc Cancer Res 2007 48 5421
37. A phase-1 study of MP-470, a novel orally bioavailable small molecule with Rad51 suppression activity. Tibes R, Berk GI, Fine GD, Choy GS, Tolcher AW, Proc Am Assoc Cancer Res 2008 49 4083
38. MP470, a potent oral Rad51 suppressor is safe and tolerable in first-in-human study. Tolcher AW, Berk GI, Fine GD, Choy GD, Bearss DJ, Redkar S, Tibes R, Proc Am Assoc Cancer Res 2008 49 4083
39. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H, Klein B, BMC Cancer 2010 10 198 10.1186/1471-2407- 10-198 20465808
40. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, et al. Cancer Res 2007 67 2982 2989 10.1158/0008-5472.CAN-06-4046 17409404 (Pubitemid 46724834)
41. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al. Cancer Cell 2007 12 131 144 10.1016/j.ccr.2007.07.003 17692805 (Pubitemid 47208626)
42. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Meads MB, Hazlehurst LA, Dalton WS, Clin Cancer Res 2008 14 2519 2526 10.1158/1078-0432.CCR-07-2223 18451212
43. Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity. Zhang W, Huang P, Cancer Biol Ther 2011 11 150 156 10.4161/cbt.11.2.14623 21191189
44. Imatinib as a paradigm of targeted therapies. Druker BJ, Adv Cancer Res 2004 91 1 30 15327887 (Pubitemid 39140955)
45. Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Rodrigues GA, Naujokas MA, Park M, Mol Cell Biol 1991 11 2962 2970 1710022 (Pubitemid 21895681)
46. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Borset M, Clin Cancer Res 2004 10 6686 6694 10.1158/1078-0432.CCR-04-0874 15475459 (Pubitemid 39346566)
47. Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-Ib clinical trial. Tolcher AW, Mita M, Gordon M, Rosen L, Patnaik A, Mita A, Fine GD, Choy GS, Berk GI, Proc Am Assoc Cancer Res 2008 49 403
48. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, et al. Oncogene 2007 26 3909 3919 10.1038/sj.onc.1210173 17325667 (Pubitemid 46884299)
49. Activity of the multi-targeted, receptor tyrosine kinase inhibitor MP470 against synovial sarcoma cells. Trevor K, Combs D, Mahadevan D, Bearss D, Cranmer L, Proc Am Assoc Cancer Res 2008 49 4891
50. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B, Radiat Oncol 2009 4 69 10.1186/1748-717X-4-69 20028557
51. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Tibes R, Fine G, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Tolcher AW, Cancer Chemother Pharmacol 2013 71 463 471 10.1007/s00280-012- 2019-3 23178951
52. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ, Mol Cancer Ther 2010 9 1544 1553 10.1158/1535-7163.MCT-09-1173 20484018
53. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC, J Biol Chem 2011 286 20666 20676 10.1074/jbc.M110.213801 21454604
54. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, et al. J Clin Oncol 2011 29 3307 3315 10.1200/JCO.2010.34.0570 21768463
55. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, et al. J Clin Oncol 2011 29 1271 1279 10.1200/JCO.2010.31.0367 21383285
56. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS, Cancer 2012 118 5903 5911 10.1002/cncr.27575 22605616
57. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Previdi S, Abbadessa G, Dalo F, France DS, Broggini M, Mol Cancer Ther 2012 11 214 223 10.1158/1535-7163.MCT-11-0277 22027690
58. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, et al. Cancer 2012 118 5894 5902 10.1002/cncr.27582 22605650
59. Targeting the pro-survival protein c-MET with ARQ 197 inhibits growth of multiple myeloma cells. Zaman S, Stellrecht CM, Shentu S, Orlowski R, Gandhi V, Proc Am Assoc Cancer Res 2012 53 844
60. Phase II study of the c-Met inhibitor ARQ 197 (tivantinib) in patients with relapsed multiple myeloma. Dorkhom SJ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Anderson ML, Baladandayuthapani V, Lin YH, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 2976
61. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, et al. Immunity 1999 10 105 115 10.1016/S1074-7613(00)80011-4 10023775 (Pubitemid 29077388)
62. Development and characterization of a Melphalan-resistant human multiple myeloma cell line. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM, Cancer Res 1991 51 995 1002 1988143
63. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Manshouri T, Estrov Z, Quintas-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S, Cancer Res 2011 71 3831 3840 10.1158/0008-5472.CAN-10-4002 21512135
64. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST, Cancer Res 2001 61 5474 5479 11454694 (Pubitemid 32694929)
65. Evidence of a role for activation of Wnt/b-catenin signaling in the resistance of plasma cells to lenalidomide. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang ML, Shah JJ, Orlowski RZ, J Biol Chem 2011 286 11009 11020 10.1074/jbc.M110.180208 21189262
66. A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Stellrecht CM, Ayres M, Arya R, Gandhi V, Breast Cancer Res Treat 2010 121 355 364 10.1007/s10549-009-0481-3 19641990